The Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Size is valued at 79.89 Million in 2022 and is predicted to reach 1077.17 Million by the year 2031 at a 28.9 % CAGR during the forecast period for 2023-2031.
The Human Microbiome is the group of loads of microbes living on and in the human body. The microbiomes are found, for example, in the skin, gut, mouth, and vagina. A live biotherapeutic product comprises a live microorganism used for the cure or treatment and prevention of disease. The live biotherapeutic industry is experiencing enormous research and development activities to develop products for various diseases and applications.
Till now, about 200 companies are developing microbiome-based therapies anticipated to treat an extensive range of severe diseases, with big pharmaceutical companies showing augmented interest by associating with early innovators. Most of the clinical treatment is under the preclinical stage, various are under clinical development, and about 15 are in phase II/III trials of development. The commercialization of these products in the coming years is expected to generate a huge potential for the growth of the market over the estimated timeframe. However, the lack of a satisfactory manufacturing capacity of the innovators may significantly hinder the market's growth. Additionally, lack of the essential industry standards associated with live biotherapeutics manufacturing, batch-to-batch reliability-related concerns, lack of infrastructure, and uncertainties related to product approval and regulatory review are some of the factors affecting market growth substantially. However, a growing number of deals among various developers for contract manufacturing is projected to generate immense opportunities for the market's growth globally.
Market Segmentation
The Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market is segmented on the basis of product manufactured, type of formulation, the scale of operation, company size, and region. The market is divided into Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) based on the product manufactured. Based on the type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on the scale of operation, the market is categorized into, preclinical scale operations, clinical scale operations, and commercial-scale operations. By company size, live biotherapeutic products and microbiome contract manufacturing market is segmented into small-sized companies, mid-sized companies, and large companies. Also, in case of applications segment it is catagorised as C.difficle, Crohns disease, IBS, Diabetes and Others. Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA.
Competitive Landscape
Some major key players in the Live Biotherapeutic Products And Microbiome Contract Manufacturing Market:
- Quay Pharmaceuticals,
- Cobra Biologics Limited,
- Cerbios-Pharma SA,
- List Biological Labs, Inc.,
- Arranta Bio,
- BacThera,
- Luina Bio Pty Ltd,
- 4D pharma plc,
- Paras Biopharmaceuticals Finland Oy,
- Capsugel, Deerland Probiotics & Enzymes,
- Paragon Bioservices,
- UAS Labs,
- Biose,
- Cobra Biologics,
- Cerbios,
- Inpac Probiotics,
- BJP Laboratories,
- S-Biomedic,
- Meteoric Biopharmaceuticals,
- BiomX,
- Universal Stabilization Technologies,
- Assembly Biosciences,
- Wacker Biotech,
- Chung Mei Pharmaceutical
- Lonza
Live Biotherapeutic Products And Microbiome Contract Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 79.89 Million |
|
Revenue Forecast In 2031 |
USD 1077.17 Million |
|
Growth Rate CAGR |
CAGR of 28.9 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Manufactured, Type of Formulations, Scale of operations, Company size, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Quay Pharmaceuticals, Cobra Biologics Limited, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio, BacThera, Luina Bio Pty Ltd, 4D pharma plc, Paras Biopharmaceuticals Finland Oy, Capsugel, Deerland Probiotics & Enzymes, Paragon Bioservices, UAS Labs, Biose, Cobra Biologics, Cerbios, Inpac Probiotics, BJP Laboratories, S-Biomedic, Meteoric Biopharmaceuticals, BiomX, Universal Stabilization Technologies, Assembly Biosciences, Wacker Biotech, and Chung Mei Pharmaceutical, Lonza. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
